Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $38.9 million, up from $21.5 million in Q4 2024, primarily due to a technology transfer agreement with Merck [21] - For the full year 2025, revenue was $70.4 million compared to $59.3 million in 2024 [21] - Product gross margin for Q4 2025 was 64%, consistent with the full year 2025 gross margin, which also stood at 64%, up from 56% in the prior year [22] - Net income for Q4 2025 was $9.6 million, compared to a net loss of $10.4 million in Q4 2024; net loss for the full year 2025 was $44 million, improved from a loss of $65.3 million in 2024 [24][25] Business Line Data and Key Metrics Changes - The small molecule biocatalysis business returned to a healthy profit margin, with stabilization in revenue, supported by a robust pipeline of drugs in late-stage clinical studies [10] - The ECO Synthesis platform achieved significant milestones, including synthesizing 10 grams of commercially relevant siRNA and scaling production to 100 grams, with plans to reach half a kilo by the end of 2026 [6][7] Market Data and Key Metrics Changes - The total addressable annual market for production technologies in five years is estimated to be $2 billion, with a growing demand for siRNA medicines at a rate of 5%-10% per year [5] - The industry is projected to require 10-30 metric tons of oligonucleotide material by 2030, indicating a significant addressable market for the company [57] Company Strategy and Development Direction - The company is focused on establishing itself as a key technology provider in the RNA medicine market through its ECO Synthesis platform, which aims to address challenges in siRNA production [4][5] - Plans include scaling up production capabilities, achieving GMP certification, and expanding partnerships with CDMOs to enhance manufacturing processes [8][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of the ECO Synthesis platform and the overall siRNA market, highlighting the importance of innovation and customer collaboration [12][28] - The company aims to demonstrate proof of success through new contracts and licensing deals in 2026, while maintaining a focus on financial performance and expense management [27][29] Other Important Information - The company ended 2025 with $78.2 million in cash equivalents, expected to fund operations and capital expenditures through the end of 2027 [25] - A restructuring charge of $3.4 million was recorded in Q4 2025 as part of efforts to reduce operating costs and improve gross margins [24] Q&A Session Summary Question: Potential value of stereoisomer control - Management is actively exploring the biological activity of stereo configurations and plans to present data at the TIDES USA meeting, with several customers interested in collaboration [31][32] Question: Understanding the recent deal process - The recent deal involved a small organization with a cardiovascular asset, highlighting the long-term discussions and mutual excitement about the ECO Synthesis platform's capabilities [35][39] Question: Details on the 50-gram contract - The initial agreement is for preclinical work, with expectations that successful data will lead to IND submissions and larger contracts for clinical trials [41][43] Question: Revenue guidance visibility - Management indicated a significant portion of the $72 million-$76 million revenue guidance is based on historical buying practices, though some estimates remain speculative at the beginning of the year [50][51] Question: Growth expectations for biocatalysis business - The small molecule biocatalysis business is expected to stabilize and continue to fuel growth, while higher growth rates are anticipated from the ECO side of the business [62][65]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $38.9 million, up from $21.5 million in Q4 2024, primarily due to a technology transfer agreement with Merck [20] - For the full year 2025, revenue was $70.4 million compared to $59.3 million in 2024 [20] - Product gross margin for Q4 2025 was 64%, consistent with the full year 2025 gross margin, which also stood at 64%, an increase from 56% in the prior year [20][21] - Net income for Q4 2025 was $9.6 million, compared to a loss of $10.4 million in Q4 2024, while the net loss for the full year 2025 was $44 million, down from $65.3 million in 2024 [24][25] Business Line Data and Key Metrics Changes - The small molecule biocatalysis business returned to a healthy profit margin in 2025, with stabilization in revenue expected to fuel growth for the next 3-5 years [9] - The ECO Synthesis platform achieved significant milestones, including synthesizing 10 grams of commercially relevant siRNA and scaling up production to 100 grams, with plans to reach half a kilo by the end of 2026 [5][6] Market Data and Key Metrics Changes - The total addressable annual market for production technologies in RNA medicine is estimated to be $2 billion in five years, with a growing demand for siRNA medicines at a rate of 5%-10% per year [4][5] - The industry is projected to require 10-30 metric tons of oligonucleotide material by 2030, indicating a significant addressable market for the company [55] Company Strategy and Development Direction - The company aims to establish itself as a key technology provider in the RNA medicine market, focusing on the ECO Synthesis platform to address production challenges [4][5] - Plans for 2026 include scaling up the ECO Synthesis manufacturing platform, achieving half-kilogram scale, and beginning construction of a GMP facility to support customer needs [7][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand for siRNA therapeutics and the company's ability to meet this demand through innovative technology [55] - The company anticipates that 2026 will be a year of significant progress, with a revenue target of $72 million to $76 million, and expects to maintain stable gross margins [25][27] Other Important Information - The company ended 2025 with $78.2 million in cash equivalents, expected to fund operations and capital expenditures through the end of 2027 [25] - A restructuring charge of $3.4 million was recorded in Q4 2025 as part of efforts to reduce operating costs and improve gross margins [24] Q&A Session Summary Question: Potential value for stereoisomer control - Management is actively exploring the biological activity of stereo configurations generated by the ECO Synthesis platform and plans to present data at the TIDES USA meeting [31][32] Question: Understanding the recent announced deal - The recent deal involves a small organization with a cardiovascular asset, and discussions have been ongoing for many months to address their manufacturing challenges [35][39] Question: Details on the 50-gram contract - The initial agreement is for preclinical work, and if successful, the company will progress to IND submissions and potentially commercial agreements for larger quantities [41][43] Question: Revenue guidance visibility - Management indicated that a significant portion of the $72 million-$76 million revenue guidance is based on historical buying practices, with some speculative elements due to the early part of the year [49][50] Question: Industry demand for siRNA - Management noted that the siRNA therapeutic pipeline is vibrant, with a growing number of assets in clinical trials, projecting a significant increase in demand by 2030 [53][55] Question: Revenue mix and growth expectations - The company expects growth to primarily come from the ECO side of the business, while the small molecule biocatalysis business is expected to stabilize and contribute to growth over the next few years [60][63]

Core Insights - Codexis, Inc. reported a total revenue of $70.4 million for the fiscal year ended December 31, 2025, representing a 19% increase from $59.3 million in 2024, primarily driven by a Technology Transfer Agreement with Merck [10] - The company ended the year with $78.2 million in cash, cash equivalents, and short-term investments, providing a runway through 2027 [10] - The net loss for fiscal year 2025 was $44.0 million, or $0.50 per share, an improvement from a net loss of $65.3 million, or $0.89 per share, in 2024 [10] Financial Highlights - Fourth quarter revenue reached $38.9 million, an 81% increase compared to $21.5 million in Q4 2024, also attributed to the Merck agreement [10] - Product gross margin improved to 64% for the fiscal year 2025, up from 56% in 2024, due to a shift towards more profitable products [10] - Research & Development expenses for 2025 were $52.3 million, an increase from $46.3 million in 2024, driven by higher employee-related costs [10] Business Developments - Codexis engaged with over 40 companies on 55 potential opportunities, transitioning discussions from feasibility testing to broader contract negotiations [7] - The company signed a lease for a GMP facility, which will enable kilogram-scale manufacturing using the ECO Synthesis platform [7] - Codexis received ISO 9001 certification for its in-house manufacturing suite, supporting future commercial contracts [7] Upcoming Milestones - The company anticipates hosting presentations at the 2026 TIDES USA annual meeting to showcase data on stereoisomer configurations delivered via enzymatic synthesis [7] - Codexis plans to begin retrofit construction on its GMP facility in the second half of 2026, aiming for full production capability by the end of 2027 [7] - The company is seeking to sign a licensing deal with a major pharmaceutical company in the second half of 2026 [7]

Financial Data and Key Metrics Changes - Total revenues for Q3 2025 were $8.6 million, down from $12.8 million in Q3 2024, primarily due to variability in customers' manufacturing schedules and clinical trial progression [15] - Product gross margin increased to 64% in Q3 2025 from 61% in Q3 2024, attributed to a shift towards more profitable products [16] - Net loss for Q3 2025 was $19.6 million, or $0.22 per share, compared to a net loss of $20.6 million, or $0.29 per share, in Q3 2024 [17] Business Line Data and Key Metrics Changes - The company has transitioned from one revenue-bearing contract to 11, with 40 more in the pipeline, indicating strong commercial traction for the Eco-synthesis platform [4][5] - The historical small molecule biocatalysis business is expected to experience a decline in service revenue next year, but this will be offset by development services in the ligase and Eco-synthesis areas [12] Market Data and Key Metrics Changes - The company is moving away from promoting its historical small molecule biocatalysis business due to pricing pressures and is refocusing on the ligase and Eco-synthesis business lines [12] - There are 14 drugs using the company's enzymes in phase three clinical trials, with data readouts expected in the next 12 months, which could fuel growth in the existing pipeline [13] Company Strategy and Development Direction - The company aims to transform into a full-service manufacturing innovator in oligonucleotide manufacturing, with plans to build a GMP facility for siRNA production [4][5] - The leadership transition is designed to streamline operations and focus on Eco-synthesis, enhancing the company's ability to deliver production technologies to customers [6][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the market potential for the Eco-synthesis platform and the importance of optimizing the organization for future success [5][6] - The restructuring is expected to reduce the company's burn rate by approximately 25%, extending its financial runway through 2027 [15] Other Important Information - The company signed a supply assurance agreement with Merck, providing a vital infusion of non-dilutive cash to support business plans [11] - The company is preparing for presentations at Tides Europe, focusing on technology scaling and in-process analytics, which are expected to be impactful for commercial progress [34] Q&A Session Summary Question: Impact of leadership transition on partnership strategy - Management confirmed that the transition will not change their plans and they are encouraged by the progress made in securing early-phase contracts [20] Question: Unique capabilities of Nitto Avecia - Management highlighted Nitto Avecia's expertise in scaling technology for larger batch sizes, which is crucial for phase two, phase three, and commercial production [28] Question: Contribution of siRNA revenue to product revenue segment - Current contracts are in the service area, and while service revenue is expected to remain consistent, the source of that revenue is shifting [32] Question: Expectations for Tides Europe presentations - The company plans to showcase data on technology scaling and in-process control, which are anticipated to be first-in-class presentations for siRNA therapeutic developers [34]